Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Nuria Ortega-Joaquín
Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib
Lung Cancer Management
Related publications
Pcn172 - Cost-Effectiveness Analysis of Alectinib in Untreated Alk-Rearranged NSCLC Italian Patients
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Alectinib Provides a New Option for ALK-positive NSCLC Patients After Progression on Crizotinib
Journal of Community and Supportive Oncology
Oncology
Hematology
The Potential Role of HGF-MET Signaling and Autophagy in the War of Alectinib Versus Crizotinib Against ALK-positive NSCLC
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
P044 Cost-Effectiveness Analysis of Icotinib vs Whole-Brain Irradiation in NSCLC Patients With Brain Metastases
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Pcn82 - Budget Impact Analysis of Alectinib for the Treatment of Patients With Untreated Alk-Rearranged NSCLC in Italy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient
Molecular and Clinical Oncology
Cancer Research
Oncology